Assignee
ACCELERON PHARMA INC
US·135 granted patents·139 pending applications·1,546 citations·filing 2005–2025
Top patents by PatentIndex Score
274 records- 0199US10973880B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Apr 13, 2021·7 cites·29 claims
- 0299US8343933B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2010·Granted Jan 1, 2013·91 cites·25 claims
- 0399US7842663B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2008·Granted Nov 30, 2010·135 cites·15 claims
- 0499US7709605B2ActRII receptor polypeptides, methods and compositionsACCELERON PHARMA INC·Filed 2005·Granted May 4, 2010·145 cites·29 claims
- 0599US7612041B2Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growthACCELERON PHARMA INC·Filed 2006·Granted Nov 3, 2009·132 cites·30 claims
- 0698US11219666B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Jan 11, 2022·5 cites·29 claims
- 0798US11065303B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Jul 20, 2021·6 cites·26 claims
- 0898US10946067B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Mar 16, 2021·6 cites·30 claims
- 0998US10889626B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Jan 12, 2021·4 cites·25 claims
- 1098US10829532B2Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2020·Granted Nov 10, 2020·4 cites·24 claims
- 1198US10722558B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2017·Granted Jul 28, 2020·15 cites·42 claims
- 1298US10695405B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2018·Granted Jun 30, 2020·13 cites·17 claims
- 1398US8361957B2Isolated GDF trap polypeptideACCELERON PHARMA INC·Filed 2011·Granted Jan 29, 2013·42 cites·14 claims
- 1498US7988973B2Activin-ActRII antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2007·Granted Aug 2, 2011·108 cites·37 claims
- 1598US7951771B2Activin-ActRIIa antagonists and uses for promoting bone growthACCELERON PHARMA INC·Filed 2008·Granted May 31, 2011·56 cites·17 claims
- 1697US10487144B2Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptideACCELERON PHARMA INC·Filed 2017·Granted Nov 26, 2019·16 cites·21 claims
- 1797US10377996B2Methods of identifying ActRIIB variantsACCELERON PHARMA INC·Filed 2016·Granted Aug 13, 2019·24 cites·11 claims
- 1897US10259861B2Variants derived from ActRIIB and uses thereforACCELERON PHARMA INC·Filed 2016·Granted Apr 16, 2019·22 cites·11 claims
- 1997US10131700B2Methods for treating refractory anemia with ringed sideroblastsACCELERON PHARMA INC·Filed 2017·Granted Nov 20, 2018·20 cites·25 claims
- 2097US9932379B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2016·Granted Apr 3, 2018·19 cites·12 claims
- 2197US9850298B2Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptideACCELERON PHARMA INC·Filed 2015·Granted Dec 26, 2017·23 cites·26 claims
- 2297US9745559B2Method for decreasing the body fat content in a subject by administering an ActRIIB proteinACCELERON PHARMA INC·Filed 2015·Granted Aug 29, 2017·22 cites·20 claims
- 2397US9353356B2Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumorACCELERON PHARMA INC·Filed 2013·Granted May 31, 2016·36 cites·45 claims
- 2497US8367611B2Activin-actriia antagonists for inhibiting germ cell maturationACCELERON PHARMA INC·Filed 2011·Granted Feb 5, 2013·35 cites·19 claims
- 2597US8007809B2Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2008·Granted Aug 30, 2011·83 cites·37 claims
- 2697US7960343B2Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretionACCELERON PHARMA INC·Filed 2008·Granted Jun 14, 2011·48 cites·40 claims
- 2796US11622992B2Compositions and methods for treating pulmonary hypertensionACCELERON PHARMA INC·Filed 2020·Granted Apr 11, 2023·3 cites·20 claims
- 2896US10689427B2Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levelsACCELERON PHARMA INC·Filed 2018·Granted Jun 23, 2020·7 cites·17 claims
- 2996US10550170B2Methods for treating vascular eye disorders with actrii antagonistsACCELERON PHARMA INC·Filed 2016·Granted Feb 4, 2020·21 cites·44 claims
- 3096US10358633B2Method for producing an ActRIIB-Fc fusion polypeptideACCELERON PHARMA INC·Filed 2017·Granted Jul 23, 2019·15 cites·7 claims
- 3196US9809637B2Transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2016·Granted Nov 7, 2017·19 cites·9 claims
- 3296US9617319B2ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapyACCELERON PHARMA INC·Filed 2014·Granted Apr 11, 2017·21 cites·24 claims
- 3396US9505813B2Use of GDF traps to treat anemiaACCELERON PHARMA INC·Filed 2013·Granted Nov 29, 2016·20 cites·63 claims
- 3496US9439945B2Isolated nucleotide sequences encoding GDF trapsACCELERON PHARMA INC·Filed 2014·Granted Sep 13, 2016·18 cites·15 claims
- 3596US9399669B2Variants derived from ActRIIBACCELERON PHARMA INC·Filed 2012·Granted Jul 26, 2016·27 cites·29 claims
- 3696US9181533B2Truncated ACTRIIB-FC fusion proteinACCELERON PHARMA INC·Filed 2012·Granted Nov 10, 2015·26 cites·19 claims
- 3796US9163075B2Isolated polynucleotide that encodes an ActRIIa-Fc fusion polypeptideACCELERON PHARMA INC·Filed 2013·Granted Oct 20, 2015·20 cites·33 claims
- 3894US10189882B2Methods for treating myelodysplastic syndromes and sideroblastic anemiasACCELERON PHARMA INC·Filed 2015·Granted Jan 29, 2019·21 cites·25 claims
- 3994US9919030B2Follistatin fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2015·Granted Mar 20, 2018·5 cites·23 claims
- 4093US11028145B2ALK7:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jun 8, 2021·4 cites·23 claims
- 4193US10358476B2Single arm type I and type II receptor fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Jul 23, 2019·12 cites·16 claims
- 4293US10227393B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·9 cites·27 claims
- 4393US7807631B2Methods of promoting growth of muscle tissue using ALK7ACCELERON PHARMA INC·Filed 2008·Granted Oct 5, 2010·15 cites·67 claims
- 4492US10093707B2Antagonists of activin-ActRIIa and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2014·Granted Oct 9, 2018·16 cites·6 claims
- 4592US10071135B2Method of identifying an agent that promotes bone growth or increases bone densityACCELERON PHARMA INC·Filed 2015·Granted Sep 11, 2018·6 cites·12 claims
- 4692US7316998B2Cerberus/Coco derivatives and uses thereofACCELERON PHARMA INC·Filed 2005·Granted Jan 8, 2008·16 cites·21 claims
- 4791US11279746B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Mar 22, 2022·2 cites·11 claims
- 4891US10968282B2Methods for screening compounds for increasing thermogenic adipocytesACCELERON PHARMA INC·Filed 2019·Granted Apr 6, 2021·2 cites·15 claims
- 4991US10738098B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Aug 11, 2020·6 cites·33 claims
- 5091US7456149B2ALK7 and myostatin inhibitors and uses thereofACCELERON PHARMA INC·Filed 2005·Granted Nov 25, 2008·11 cites·4 claims
Showing the top 50 of 274 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ACCELERON PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →